Alaunos Therapeutics, Inc.
About Alaunos Therapeutics, Inc.
Alaunos Therapeutics Inc is a preclinical-stage biopharmaceutical company focused on the development of novel, orally administered small-molecule therapeutics for obesity and related metabolic disorders, such as metabolic dysfunction-associated steatotic liver disease (MASLD, a type of fatty liver disease). The program aims to develop a differentiated, non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. It has a single reportable and operating segment related to biopharmaceutical research and development.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $5.0K
- Net income
- -$4.2M
- Total assets
- $3.0M
- Market cap
- $5.6M
Source: SEC EDGAR · updated Jun 7, 2026
- Market cap
- $5.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Aug 24, 2005
Market data by Polygon.io · prices are 15-minute delayed
No reviews yet. Be the first to review Alaunos Therapeutics, Inc..